Table 3 Treatment and outcomes of critically ill COVID-19 patients stratified by IFNL4 rs12979860 genotype.
Overall (n = 184) | CC/CT (n = 154) | TT (n = 19) | p-value | |
|---|---|---|---|---|
Treatment | ||||
Corticosteroids, n (%) | 158 (85.9) | 132 (85.7) | 18 (94.7) | 0.462 |
Antiviral agent, n (%) | 152 (82.6) | 127 (82.5) | 16 (84.2) | 1.000 |
Remdesivir, n (%) | 24 (13.0) | 20 (13.0) | 2 (10.5) | 0.999 |
Vasopressor, n (%) | 106 (57.6) | 88 (57.1) | 11 (57.9) | 0.999 |
Acute kidney injury | ||||
AKI KDIGO I, n (%) | 13 (7.1) | 12 (7.8) | 1 (5.3) | |
AKI KDIGO II, n (%) | 10 (5.4) | 9 (5.8) | 0 (0.0) | |
AKI KDIGO III, n (%) | 27 (14.7) | 19 (12.3) | 5 (26.3) | |
Renal replacement therapy, n (%) | 27 (14.7) | 18 (11.7) | 6 (31.6) | 0.044 |
Invasive Mechanical Ventilation, n (%) | 112 (60.9) | 94 (61.0) | 11 (57.9) | 0.987 |
Duration of IMV, days | 18 [11–30] | 15 [10–26] | 22 [20–37] | 0.018 |
Outcome | ||||
Death in the ICU, n (%) | 35 (19.0) | 26 (16.9) | 4 (21.1) | 0.895 |
Death in the Hospital, n (%) | 41 (22.3) | 30 (19.5) | 6 (31.6) | 0.354 |
ICU length of stay, days | 16 [8–27] | 16 [8–25] | 23 [10–35] | 0.218 |
Hospital length of stay, days | 28 [18–47] | 27 [18–45] | 30 [22–78] | 0.169 |
